Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHA:600276)
48.46
-0.16 (-0.33%)
Oct 30, 2026, 3:00 PM CST
SHA:600276 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 32,850 | 31,629 | 27,985 | 22,820 | 21,275 | 25,906 |
Revenue Growth | 6.02% | 13.02% | 22.63% | 7.26% | -17.87% | -6.59% |
Gross Profit Gross Profit Growth | 28,370 | 27,180 | 24,104 | 19,257 | 17,772 | 22,150 |
Operating Income Operating Income Growth | 9,013 | 8,086 | 6,476 | 4,176 | 3,060 | 3,765 |
Net Income Net Income Growth | 8,883 | 7,711 | 6,337 | 4,302 | 3,906 | 4,530 |
Earnings Per Share EPS Growth | 1.34 | 1.18 | 1.00 | 0.68 | 0.61 | 0.71 |
EPS Growth | 15.42% | 18.00% | 47.06% | 11.47% | -14.09% | -28.28% |
Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
China China Growth | 26,859 |
Foreign Foreign Growth | 4,771 |
Total Total Growth | 31,629 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 43,560 | 41,069 | 25,089 | 20,845 | 17,871 | 18,721 |
Total Debt Total Debt Growth | 421.65 | 74.23 | 110.16 | 75.18 | 1,360 | 151.59 |
Net Cash (Debt) Net Cash Growth | 43,138 | 40,995 | 24,979 | 20,770 | 16,511 | 18,570 |
Net Cash Growth | 6.80% | 64.12% | 20.27% | 25.79% | -11.08% | 13.00% |
Net Cash Per Share Net Cash Per Share Growth | 6.50 | 6.27 | 3.94 | 3.28 | 2.58 | 2.91 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 9,969 | 11,235 | 7,423 | 7,644 | 1,265 | 4,219 |
Capital Expenditures CapEx Growth | -3,918 | -2,962 | -1,969 | -1,484 | -1,992 | -1,665 |
Free Cash Flow Free Cash Flow Growth | 6,051 | 8,273 | 5,454 | 6,160 | -726.91 | 2,554 |
Free Cash Flow Growth | -38.19% | 51.71% | -11.47% | - | - | -11.24% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 86.36% | 85.93% | 86.13% | 84.39% | 83.53% | 85.50% |
Operating Margin | 27.44% | 25.57% | 23.14% | 18.30% | 14.38% | 14.53% |
Pretax Margin | 30.52% | 27.53% | 25.62% | 20.45% | 18.65% | 17.24% |
Profit Margin | 27.04% | 24.38% | 22.64% | 18.85% | 18.36% | 17.49% |
FCF Margin | 18.42% | 26.16% | 19.49% | 26.99% | -3.42% | 9.86% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.200 | 0.200 | 0.200 | 0.200 | 0.160 | 0.160 |
Dividend Per Share Growth | 0% | 0% | 0% | 25.00% | 0% | -4.02% |
Dividend Yield | 0.41% | 0.33% | 0.44% | 0.44% | 0.41% | 0.32% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 36.19 | 51.32 | 46.06 | 66.85 | 62.91 | 71.32 |
Forward PE | 32.85 | 38.99 | 49.34 | 56.94 | 49.45 | 52.14 |
P/FCF Ratio | 52.79 | 47.84 | 53.52 | 46.69 | - | 126.49 |
PS Ratio | 9.72 | 12.51 | 10.43 | 12.60 | 11.55 | 12.47 |